Orthofix International N.V. (OFIX) Holdings Reduced by KBC Group NV
KBC Group NV lessened its position in Orthofix International N.V. (NASDAQ:OFIX) by 25.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,199 shares of the medical device company’s stock after selling 9,377 shares during the period. KBC Group NV owned approximately 0.15% of Orthofix International worth $1,285,000 as of its most recent filing with the SEC.
A number of other large investors have also recently modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in Orthofix International by 1.2% in the third quarter. Dimensional Fund Advisors LP now owns 880,901 shares of the medical device company’s stock valued at $41,623,000 after purchasing an additional 10,781 shares in the last quarter. WINTON GROUP Ltd bought a new stake in Orthofix International in the third quarter valued at approximately $2,121,000. Wells Fargo & Company MN increased its stake in Orthofix International by 109.2% in the third quarter. Wells Fargo & Company MN now owns 27,749 shares of the medical device company’s stock valued at $1,311,000 after purchasing an additional 14,482 shares in the last quarter. Paradice Investment Management LLC increased its stake in Orthofix International by 10.0% in the third quarter. Paradice Investment Management LLC now owns 157,200 shares of the medical device company’s stock valued at $7,428,000 after purchasing an additional 14,300 shares in the last quarter. Finally, Cadence Capital Management LLC bought a new stake in Orthofix International in the third quarter valued at approximately $1,501,000. 94.61% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Brad Mason sold 5,000 shares of the stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total transaction of $267,400.00. Following the completion of the sale, the chief executive officer now owns 183,053 shares of the company’s stock, valued at $9,789,674.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Luke T. Faulstick sold 4,800 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $51.22, for a total transaction of $245,856.00. Following the sale, the director now directly owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The disclosure for this sale can be found here. 5.60% of the stock is owned by corporate insiders.
Several equities research analysts have commented on the stock. Zacks Investment Research raised shares of Orthofix International from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research note on Thursday, November 2nd. TheStreet downgraded shares of Orthofix International from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. BTIG Research set a $56.00 target price on shares of Orthofix International and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, BidaskClub raised shares of Orthofix International from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $54.42.
Shares of Orthofix International N.V. (OFIX) opened at $51.81 on Wednesday. Orthofix International N.V. has a 12-month low of $32.51 and a 12-month high of $54.73. The stock has a market cap of $946.92, a price-to-earnings ratio of 33.95, a PEG ratio of 2.58 and a beta of 0.14.
Orthofix International (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.01. Orthofix International had a net margin of 0.33% and a return on equity of 10.26%. The company had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. During the same quarter in the prior year, the firm earned $0.36 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. equities analysts anticipate that Orthofix International N.V. will post 1.61 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Orthofix International N.V. (OFIX) Holdings Reduced by KBC Group NV” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/orthofix-international-n-v-ofix-holdings-reduced-by-kbc-group-nv/1760769.html.
Orthofix International Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.